About The Study: Semaglutide and tirzepatide prescriptions within Epic-affiliated health care systems increased slightly between 2021 and 2024, but their uptake remained limited, with only 3% of eligible patients having ever received a prescription during that period. Furthermore, there were disparities in prescribing of varying magnitude based on race and ethnicity, social vulnerability, and urbanicity, although the absolute differences were small compared with the overall underutilization.
Corresponding Author: To contact the corresponding author, Yuan Lu, ScD, email y.lu@yale.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.4735)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.4735?guestAccessKey=ba29174d-ce24-48f3-926b-02e03bb82ad6&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=042925
Journal
JAMA